Novo Nordisk A/S $NVO Shares Sold by Modera Wealth Management LLC

Posted by Francis Steltz on Oct 31st, 2026

Modera Wealth Management LLC cut its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 5.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 288,276 shares of the company’s stock after selling 17,520 shares during the quarter. Modera Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $10,929,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Armstrong Fleming & Moore Inc lifted its stake in shares of Novo Nordisk A/S by 30.9% in the third quarter. Armstrong Fleming & Moore Inc now owns 6,774 shares of the company’s stock worth $257,000 after acquiring an additional 1,601 shares during the period. Laurel Wealth Advisors LLC bought a new stake in Novo Nordisk A/S in the third quarter valued at approximately $123,000. Latitude Advisors LLC acquired a new stake in Novo Nordisk A/S during the 3rd quarter valued at approximately $38,000. Ashton Thomas Securities LLC increased its position in Novo Nordisk A/S by 19.3% during the 3rd quarter. Ashton Thomas Securities LLC now owns 14,000 shares of the company’s stock valued at $531,000 after purchasing an additional 2,266 shares during the period. Finally, DMC Group LLC increased its position in Novo Nordisk A/S by 11.6% during the 3rd quarter. DMC Group LLC now owns 7,986 shares of the company’s stock valued at $303,000 after purchasing an additional 831 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $39.96 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. The firm has a fifty day simple moving average of $41.23 and a two-hundred day simple moving average of $44.34. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The firm has a market capitalization of $178.42 billion, a PE ratio of 9.74, a price-to-earnings-growth ratio of 1.33 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The firm had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. Analysts forecast that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were issued a $0.5786 dividend. The ex-dividend date was Monday, August 17th. This represents a dividend yield of 258.0%. This is a drop from Novo Nordisk A/S’s previous dividend of $1.2751. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 20.05%.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: Novo Nordisk’s new 2030 targets emphasize pipeline expansion, broader treatment offerings and the goal of serving more patients. The strategy could help reduce the company’s dependence on its current GLP-1 franchise and support a long-term recovery. Novo Nordisk Sets New 2030 Goals As GLP-1 Competition Builds
Positive Sentiment: The global weight-loss market is forecast to expand substantially through 2036, providing a large long-term opportunity for Novo Nordisk as demand grows for GLP-1 drugs, oral therapies, telehealth and direct-to-patient distribution. Global Weight Loss Market Size, Share, Trends and Forecast
Positive Sentiment: Erste Group Bank maintained a bullish outlook for Novo Nordisk’s fiscal 2026 earnings, while recent commentary argues that the shares’ sharp multi-year decline has left the company looking inexpensive relative to its earnings potential. Erste Group Bank Has Bullish Outlook for NVO FY2026 Earnings
Neutral Sentiment: Novo Nordisk is receiving elevated investor attention, but trending-stock coverage primarily highlights factors to monitor rather than a new fundamental catalyst. What to Know Beyond Why Novo Nordisk Is a Trending Stock
Negative Sentiment: Eli Lilly’s strong results and raised outlook reinforce its lead in obesity drugs, underscoring the competitive pressure facing Novo Nordisk. Investors may require stronger pipeline execution and evidence that the 2030 plan can offset slowing momentum in current GLP-1 products. Eli Lilly Jumps as Strong Quarter Lifts Revenue Outlook

Analyst Ratings Changes

A number of research analysts have recently issued reports on NVO shares. BMO Capital Markets set a $40.00 price target on shares of Novo Nordisk A/S and gave the stock a “market perform” rating in a research report on Monday, October 12th. Berenberg Bank reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Thursday, September 10th. Finally, Jefferies Financial Group restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Five investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $59.44.

Read Our Latest Research Report on Novo Nordisk A/S

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.